Information:
Fel:
ID
30861
Beskrivning
Study of Natalizumab in Relapsed/Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00675428
Länk
https://clinicaltrials.gov/show/NCT00675428
Nyckelord
Versioner (1)
- 2018-06-27 2018-06-27 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
27 juni 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Multiple Myeloma NCT00675428
Eligibility Multiple Myeloma NCT00675428
- StudyEvent: Eligibility
Similar models
Eligibility Multiple Myeloma NCT00675428
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Recurrent multiple myeloma | Refractory multiple myeloma | Bortezomib | Immunomodulators | Bortezomib Analogue | Immunomodulator Analogue | Patients Inappropriate Bortezomib | Patients Inappropriate Immunomodulators
Item
relapsed or refractory multiple myeloma that was treated with or was considered inappropriate for treatment with bortezomib and an imid® drug (including an analogue).
boolean
C1370446 (UMLS CUI [1])
C0278620 (UMLS CUI [2])
C1176309 (UMLS CUI [3])
C1527392 (UMLS CUI [4])
C1176309 (UMLS CUI [5,1])
C0243071 (UMLS CUI [5,2])
C1527392 (UMLS CUI [6,1])
C0243071 (UMLS CUI [6,2])
C0030705 (UMLS CUI [7,1])
C1548788 (UMLS CUI [7,2])
C1176309 (UMLS CUI [7,3])
C0030705 (UMLS CUI [8,1])
C1548788 (UMLS CUI [8,2])
C1527392 (UMLS CUI [8,3])
C0278620 (UMLS CUI [2])
C1176309 (UMLS CUI [3])
C1527392 (UMLS CUI [4])
C1176309 (UMLS CUI [5,1])
C0243071 (UMLS CUI [5,2])
C1527392 (UMLS CUI [6,1])
C0243071 (UMLS CUI [6,2])
C0030705 (UMLS CUI [7,1])
C1548788 (UMLS CUI [7,2])
C1176309 (UMLS CUI [7,3])
C0030705 (UMLS CUI [8,1])
C1548788 (UMLS CUI [8,2])
C1527392 (UMLS CUI [8,3])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status ≤2.
boolean
C1520224 (UMLS CUI [1])
Corrected serum calcium measurement
Item
corrected calcium <10.6 mg/dl.
boolean
C0455288 (UMLS CUI [1])
Exclusion Criteria Main
Item
key exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
C1542147 (UMLS CUI [1,2])
Patients Appropriate Stem cell transplant | Transplantation Receive Willing
Item
candidates for stem cell transplantation willing to undergo transplantation. (subjects who are candidates for stem cell transplantation, but are not willing to undergo transplant will be eligible for the study.)
boolean
C0030705 (UMLS CUI [1,1])
C1548787 (UMLS CUI [1,2])
C1504389 (UMLS CUI [1,3])
C0040732 (UMLS CUI [2,1])
C1514756 (UMLS CUI [2,2])
C0600109 (UMLS CUI [2,3])
C1548787 (UMLS CUI [1,2])
C1504389 (UMLS CUI [1,3])
C0040732 (UMLS CUI [2,1])
C1514756 (UMLS CUI [2,2])
C0600109 (UMLS CUI [2,3])
Transplantation of autologous hematopoietic stem cell | Time Period Post Transplantation
Item
autologous stem cell transplantation <3 months post-transplant.
boolean
C1831743 (UMLS CUI [1])
C1948053 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C0040732 (UMLS CUI [2,3])
C1948053 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C0040732 (UMLS CUI [2,3])
Allogeneic Stem Cell Transplantation
Item
prior allogeneic stem cell transplantation.
boolean
C2242529 (UMLS CUI [1])
Non-secretory myeloma
Item
nonsecretory myeloma.
boolean
C0456845 (UMLS CUI [1])
Leukemia, Plasma Cell | Circulating Plasma Cell Differential cell count method Standard | Hyperleukocytosis | White Blood Cell Count procedure | Hyperviscosity syndrome | POEMS Syndrome | Primary Systemic Amyloidosis
Item
plasma cell leukemia (>2000/µl circulating plasma cells by standard cell counting differential), hyperleukocytosis (white blood cells >100,000/µl), clinical evidence of hyperviscosity syndrome, or polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (poems), or primary systemic amyloidosis.
boolean
C0023484 (UMLS CUI [1])
C3811668 (UMLS CUI [2,1])
C2591490 (UMLS CUI [2,2])
C1442989 (UMLS CUI [2,3])
C4324336 (UMLS CUI [3])
C0023508 (UMLS CUI [4])
C0221030 (UMLS CUI [5])
C0085404 (UMLS CUI [6])
C0281479 (UMLS CUI [7])
C3811668 (UMLS CUI [2,1])
C2591490 (UMLS CUI [2,2])
C1442989 (UMLS CUI [2,3])
C4324336 (UMLS CUI [3])
C0023508 (UMLS CUI [4])
C0221030 (UMLS CUI [5])
C0085404 (UMLS CUI [6])
C0281479 (UMLS CUI [7])
MRI Receive Unable
Item
subjects who cannot undergo a brain magnetic resonance imaging (mri) study.
boolean
C0024485 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
C1514756 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
12 lead ECG Abnormality | Prolonged QTc interval | Gender
Item
clinically significant (as determined by the investigator) 12 lead electrocardiogram (ecg) abnormalities, including qtc prolongation (>450 ms in males, >470 ms in females).
boolean
C0430456 (UMLS CUI [1,1])
C1704258 (UMLS CUI [1,2])
C1560305 (UMLS CUI [2])
C0079399 (UMLS CUI [3])
C1704258 (UMLS CUI [1,2])
C1560305 (UMLS CUI [2])
C0079399 (UMLS CUI [3])
Eligibility Criteria Study Protocol
Item
note: other protocol defined inclusion/exclusion criteria may apply.
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
C2348563 (UMLS CUI [1,2])